The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?

J Allergy Clin Immunol. 2010 Sep;126(3):449-52. doi: 10.1016/j.jaci.2010.05.039. Epub 2010 Aug 7.

Authors

Robert F Lemanske Jr, William W Busse

PMID: 20692690
DOI: 10.1016/j.jaci.2010.05.039

No abstract available

Publication types

Editorial

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Adrenergic beta-Agonists / adverse effects
Adrenergic beta-Agonists / standards
Adrenergic beta-Agonists / therapeutic use*
Albuterol / adverse effects
Albuterol / analogs & derivatives*
Albuterol / standards
Albuterol / therapeutic use
Asthma / drug therapy*
Drug Dosage Calculations
Drug Labeling
Humans
Risk Factors
Salmeterol Xinafoate
Time Factors
Treatment Outcome
United States
United States Food and Drug Administration*

Substances

Adrenal Cortex Hormones
Adrenergic beta-Agonists
Salmeterol Xinafoate
Albuterol